JPY2,092.00
0.14% today
Tokyo, Sep 25, 08:15 am CET
ISIN
JP3428850006
Symbol
4559

Zeria Pharmaceutical Target price 2025 - Analyst rating & recommendation

Zeria Pharmaceutical Classifications & Recommendation:

Buy
80%
Hold
20%

Zeria Pharmaceutical Price Target

Target Price JPY2,448.00
Price JPY2,092.00
Potential
Number of Estimates 3
3 Analysts have issued a price target Zeria Pharmaceutical 2026 . The average Zeria Pharmaceutical target price is JPY2,448.00. This is higher than the current stock price. The highest price target is
JPY2,520.00 20.46%
register free of charge
, the lowest is
JPY2,424.00 15.87%
register free of charge
.
A rating was issued by 5 analysts: 4 Analysts recommend Zeria Pharmaceutical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Zeria Pharmaceutical stock has an average upside potential 2026 of . Most analysts recommend the Zeria Pharmaceutical stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Mar '25 2026
Estimates
Revenue Billion JPY 87.31 90.90
15.30% 4.11%
EBITDA Margin 20.67% 22.67%
4.76% 9.67%
Net Margin 11.38% 9.89%
11.47% 13.10%

2 Analysts have issued a sales forecast Zeria Pharmaceutical 2026 . The average Zeria Pharmaceutical sales estimate is

JPY90.9b
Unlock
. This is
6.51% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
JPY94.5b 10.73%
Unlock
, the lowest is
JPY88.2b 3.35%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 JPY87.3b 15.30%
2026
JPY90.9b 4.11%
Unlock
2027
JPY95.1b 4.67%
Unlock
2028
JPY99.9b 4.99%
Unlock

2 Zeria Pharmaceutical Analysts have issued a net profit forecast 2026. The average Zeria Pharmaceutical net profit estimate is

JPY9.0b
Unlock
. This is
31.91% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
JPY9.3b 37.13%
Unlock
, the lowest is
JPY8.7b 27.99%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 JPY9.9b 28.52%
2026
JPY9.0b 9.54%
Unlock
2027
JPY10.2b 13.47%
Unlock
2028
JPY11.0b 7.94%
Unlock

Net Margin

2025 11.38% 11.47%
2026
9.89% 13.10%
Unlock
2027
10.72% 8.39%
Unlock
2028
11.02% 2.80%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Mar '25 2026
Estimates
Earnings Per Share JPY 225.42 203.92
28.53% 9.54%
P/E 10.27
EV/Sales 1.21

2 Analysts have issued a Zeria Pharmaceutical forecast for earnings per share. The average Zeria Pharmaceutical EPS is

JPY203.92
Unlock
. This is
31.91% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
JPY212.00 37.14%
Unlock
, the lowest is
JPY197.86 27.99%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 JPY225.42 28.53%
2026
JPY203.92 9.54%
Unlock
2027
JPY231.39 13.47%
Unlock
2028
JPY249.77 7.94%
Unlock

P/E ratio

Current 13.55 23.53%
2026
10.27 24.22%
Unlock
2027
9.05 11.88%
Unlock
2028
8.39 7.29%
Unlock

Based on analysts' sales estimates for 2026, the Zeria Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.29 29.12%
2026
1.21 5.92%
Unlock
2027
1.16 4.46%
Unlock
2028
1.10 4.75%
Unlock

P/S ratio

Current 1.08 28.83%
2026
1.01 6.11%
Unlock
2027
0.97 4.46%
Unlock
2028
0.92 4.75%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today